MCP
MRVI icon

Mirador Capital Partners’s Maravai LifeSciences MRVI Stock Holding History

Mirador Capital Partners’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,416
Closed -$226K – 194
2022
Q1 		$226K Sell
6,416
-7,741
-55% -$260K 0.05% 189
2021
Q4 		$593K Sell
14,157
-4,665
-25% -$189K 0.12% 125
2021
Q3 		$924K Buy
+18,822
New +$918K 0.21% 101

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Mirador Capital Partners's MRVI Position: Q2 2022 in Review

Mirador Capital Partners sold out of Maravai LifeSciences (MRVI) in Q2 2022, closing a stake of 6,416 shares — an estimated $226K sold.

Mirador Capital Partners first reported a position in MRVI in Q3 2021 and held it in 3 quarters. The position peaked at $924K in Q3 2021. 216 funds tracked by Wall St. Rank hold MRVI as of Q2 2022.

  • Mirador Capital Partners reported no remaining Maravai LifeSciences position as of Q2 2022 after selling out during the quarter.
  • Mirador Capital Partners sold 6,416 Maravai LifeSciences shares in Q2 2022, an estimated $226K.
  • Mirador Capital Partners first reported a position in Maravai LifeSciences in Q3 2021 and held it in 3 quarters.
  • Mirador Capital Partners's Maravai LifeSciences position peaked at $924K in Q3 2021.
  • 216 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2022.

Based on Mirador Capital Partners's 13F filing for Q2 2022, filed 5 Aug 2022.